Used in the treatment of eye diseases involving abnormal blood vessel growth, such as wet age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion. It works by blocking vascular endothelial growth factor (VEGF), a protein that promotes the formation of leaky blood vessels in the retina. By inhibiting VEGF, this antibody helps reduce retinal swelling, slow vision loss, and in some cases improve visual acuity. It serves as a reference standard in biosimilar development and preclinical research for evaluating the efficacy and binding characteristics of new anti-VEGF therapeutics. Also utilized in comparative studies to assess drug performance in ophthalmic formulations and delivery systems.